Comparative efficacy of a secretory phospholipase A2 inhibitor with conventional anti-inflammatory agents in a rat model of antigen-induced arthritis

Arthritis Research and Therapy

Volumn 13, Issue 2, 2011, Pages

  Coulthard, Liam G ^a   Costello, Jaclyn ^a   Robinson, Brent ^a   Shiels, Ian A ^a   Taylor, Stephen M ^a   Woodruff, Trent M ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

5 (4 BENZYLOXYPHENYL) (7 PHENYLHEPTANOYLAMINO) PENTANOIC ACID; INFLIXIMAB; LEFLUNOMIDE; PHOSPHOLIPASE A2; PHOSPHOLIPASE A2 INHIBITOR; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; ENZYME INHIBITOR; SECRETORY PHOSPHOLIPASE A2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; GAIT DISORDER; HISTOPATHOLOGY; JOINT SWELLING; KNEE; NONHUMAN; PROTEIN BLOOD LEVEL; RAT; RHEUMATOID ARTHRITIS; SYNOVIUM; ANIMAL; ARTHRITIS; COMPARATIVE STUDY; DISEASE MODEL; DRUG ANTAGONISM; ENZYME LINKED IMMUNOSORBENT ASSAY; PATHOLOGY; WISTAR RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ARTHRITIS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; PHOSPHOLIPASES A2, SECRETORY; RATS; RATS, WISTAR;

EID: 79952514274     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3278     Document Type: Article

References (42)

1. Abbott JD, Moreland LW. Rheumatoid arthritis: developing pharmacological therapies. Expert Opin Investig Drugs 2004, 13:1007-1018. 10.1517/13543784.13.8.1007, 15268638.
2. Pruzanski W, Vadas P, Stefanski E, Urowitz MB. Phospholipase A2 activity in sera and synovial fluids in rheumatoid arthritis and osteoarthritis. Its possible role as a proinflammatory enzyme. J Rheumatol 1985, 12:211-216.
3. Reid RC. Inhibitors of secretory phospholipase A2 group IIA. Curr Med Chem 2005, 12:3011-3026. 10.2174/092986705774462860, 16378502.
4. Chang J, Musser JH, McGregor H. Phospholipase A2: function and pharmacological regulation. Biochem Pharmacol 1987, 36:2429-2436. 10.1016/0006-2952(87)90512-0, 3300655.
5. Cupillard L, Mulherkar R, Gomez N, Kadam S, Valentin E, Lazdunski M, Lambeau G. Both group IB and group IIA secreted phospholipases A2 are natural ligands of the mouse 180-kDa M-type receptor. J Biol Chem 1999, 274:7043-7051. 10.1074/jbc.274.11.7043, 10066760.
6. Murakami M, Hara N, Kudo I, Inoue K. Triggering of degranulation in mast cells by exogenous type II phospholipase A2. J Immunol 1993, 151:5675-5684.
7. Silliman CC, Moore EE, Zallen G, Gonzalez R, Johnson JL, Elzi DJ, Meng X, Hanasaki K, Ishizaki J, Arita H, Ao L, England KM, Banerjee A. Presence of the M-type sPLA(2) receptor on neutrophils and its role in elastase release and adhesion. Am J Physiol Cell Physiol 2002, 283:C1102-C1113.
8. Woodruff TM, Ager RR, Tenner AJ, Noakes PG, Taylor SM. The role of the complement system and the activation fragment C5a in the central nervous system. Neuromolecular Med 2010, 12:179-192. 10.1007/s12017-009-8085-y, 19763906.
9. Seilhamer JJ, Plant S, Pruzanski W, Schilling J, Stefanski E, Vadas P, Johnson LK. Multiple forms of phospholipase A2 in arthritic synovial fluid. J Biochem 1989, 106:38-42.
10. Pruzanski W, Keystone EC, Sternby B, Bombardier C, Snow KM, Vadas P. Serum phospholipase A2 correlates with disease activity in rheumatoid arthritis. J Rheumatol 1988, 15:1351-1355.
11. Lin MK, Farewell V, Vadas P, Bookman AA, Keystone EC, Pruzanski W. Secretory phospholipase A2 as an index of disease activity in rheumatoid arthritis. Prospective double blind study of 212 patients. J Rheumatol 1996, 23:1162-1166.
12. Masuda S, Murakami M, Komiyama K, Ishihara M, Ishikawa Y, Ishii T, Kudo I. Various secretory phospholipase A2 enzymes are expressed in rheumatoid arthritis and augment prostaglandin production in cultured synovial cells. FEBS J 2005, 272:655-672. 10.1111/j.1742-4658.2004.04489.x, 15670148.
13. Vadas P, Pruzanski W, Kim J, Fornasier V. The proinflammatory effect of intra-articular injection of soluble human and venom phospholipase A2. Am J Pathol 1989, 134:807-811. 1879795, 2705507.
14. Bomalaski JS, Lawton P, Browning JL. Human extracellular recombinant phospholipase A2 induces an inflammatory response in rabbit joints. J Immunol 1991, 146:3904-3910.
15. Grass DS, Felkner RH, Chiang MY, Wallace RE, Nevalainen TJ, Bennett CF, Swanson ME. Expression of human group II PLA2 in transgenic mice results in epidermal hyperplasia in the absence of inflammatory infiltrate. J Clin Invest 1996, 97:2233-2241. 10.1172/JCI118664, 507302, 8636402.
16. Fox N, Song M, Schrementi J, Sharp JD, White DL, Snyder DW, Hartley LW, Carlson DG, Bach NJ, Dillard RD, Draheim SE, Bobbitt JL, Fisher L, Mihelich ED. Transgenic model for the discovery of novel human secretory non-pancreatic phospholipase A2 inhibitors. Eur J Pharmacol 1996, 308:195-203. 10.1016/0014-2999(96)00257-9, 8840132.
17. Bradley JD, Dmitrienko AA, Kivitz AJ, Gluck OS, Weaver AL, Wiesenhutter C, Myers SL, Sides GD. A randomized, double-blinded, placebo-controlled clinical trial of LY333013, a selective inhibitor of group II secretory phospholipase A2, in the treatment of rheumatoid arthritis. J Rheumatol 2005, 32:417-423.
18. Pruzanski W. Phospholipase A2: quo vadis?. J Rheumatol 2005, 32:400-402.
19. Arumugam TV, Arnold N, Proctor LM, Newman M, Reid RC, Hansford KA, Fairlie DP, Shiels IA, Taylor SM. Comparative protection against rat intestinal reperfusion injury by a new inhibitor of sPLA2, COX-1 and COX-2 selective inhibitors, and an LTC4 receptor antagonist. Br J Pharmacol 2003, 140:71-80. 10.1038/sj.bjp.0705402, 1574000, 12967936.
20. Woodruff TM, Arumugam TV, Shiels IA, Newman ML, Ross PA, Reid RC, Fairlie DP, Taylor SM. A potent and selective inhibitor of group IIa secretory phospholipase A2 protects rats from TNBS-induced colitis. Int Immunopharmacol 2005, 5:883-892. 10.1016/j.intimp.2005.01.003, 15778124.
21. Hansford KA, Reid RC, Clark CI, Tyndall JDA, Whitehouse MW, Guthrie T, McGeary RP, Schafer K, Martin JL, Fairlie DP. D-Tyrosine as a chiral precusor to potent inhibitors of human nonpancreatic secretory phospholipase A2 (IIa) with antiinflammatory activity. Chembiochem 2003, 4:181-185. 10.1002/cbic.200390029, 12616631.
22. Griffiths RJ. Characterisation and pharmacological sensitivity of antigen arthritis induced by methylated bovine serum albumin in the rat. Agents Actions 1992, 35:88-95. 10.1007/BF01990957, 1509982.
23. Woodruff TM, Strachan AJ, Dryburgh N, Shiels IA, Reid RC, Fairlie DP, Taylor SM. Antiarthritic activity of an orally active C5a receptor antagonist against antigen-induced monarticular arthritis in the rat. Arthritis Rheum 2002, 46:2476-2485. 10.1002/art.10449, 12355496.
24. Woodruff TM, Arumugam TV, Shiels IA, Reid RC, Fairlie DP, Taylor SM. A potent human C5a receptor antagonist protects against disease pathology in a rat model of inflammatory bowel disease. J Immunol 2003, 171:5514-5520.
25. Woodruff TM, Crane JW, Proctor LM, Buller KM, Shek AB, de Vos K, Pollitt S, Williams HM, Shiels IA, Monk PN, Taylor SM. Therapeutic activity of C5a receptor antagonists in a rat model of neurodegeneration. FASEB J 2006, 20:1407-1417. 10.1096/fj.05-5814com, 16816116.
26. Matsuura M, Imayoshi T, Okumoto T. Effect of FTY720, a novel immunosuppressant, on adjuvant- and collagen-induced arthritis in rats. Int J Immunopharmacol 2000, 22:323-331. 10.1016/S0192-0561(99)00088-0, 10689105.
27. Paul-Clark MJ, Mancini L, Del Soldato P, Flower RJ, Perretti M. Potent antiarthritic properties of a glucocorticoid derivative, NCX-1015, in an experimental model of arthritis. Proc Natl Acad Sci USA 2002, 99:1677-1682. 10.1073/pnas.022641099, 122250, 11805287.
28. Magari K, Miyata S, Nishigaki F, Ohkubo Y, Mutoh S. Comparison of anti-arthritic properties of leflunomide with methotrexate and FK506: effect on T cell activation-induced inflammatory cytokine production in vitro and rat adjuvant-induced arthritis. Inflamm Res 2004, 53:544-550. 10.1007/s00011-004-1294-9, 15597149.
29. Triggiani M, Granata F, Giannattasio G, Marone G. Secretory phospholipases A2 in inflammatory and allergic diseases: not just enzymes. J Allergy Clin Immunol 2005, 116:1000-1006. 10.1016/j.jaci.2005.08.011, 16275367.
30. Enomoto A, Murakami M, Valentin E, Lambeau G, Gelb MH, Kudo I. Redundant and segregated functions of granule-associated heparin-binding group II subfamily of secretory phospholipases A2 in the regulation of degranulation and prostaglandin D2 synthesis in mast cells. J Immunol 2000, 165:4007-4014.
31. Hernández M, Fuentes L, Fernández Avilés FJ, Crespo MS, Nieto ML. Secretory phospholipase A(2) elicits proinflammatory changes and upregulates the surface expression of fas ligand in monocytic cells: potential relevance for atherogenesis. Circ Res 2002, 90:38-45.
32. Triggiani M, Granata F, Oriente A, Gentile M, Petraroli A, Balestrieri B, Marone G. Secretory phospholipases A2 induce cytokine release from blood and synovial fluid monocytes. Eur J Immunol 2002, 32:67-76. 10.1002/1521-4141(200201)32:1<67::AID-IMMU67>3.0.CO;2-3, 11754005.
33. Sawamukai N, Saito K, Yamaoka K, Nakayamada S, Ra C, Tanaka Y. Leflunomide inhibits PDK1/Akt pathway and induces apoptosis of human mast cells. J Immunol 2007, 179:6479-6484.
34. Lee DM, Friend DS, Gurish MF, Benoist C, Mathis D, Brenner MB. Mast cells: a cellular link between autoantibodies and inflammatory arthritis. Science 2002, 297:1689-1692. 10.1126/science.1073176, 12215644.
35. Kellner H, Bornholdt K, Hein G. Leflunomide in the treatment of patients with early rheumatoid arthritis--results of a prospective non-interventional study. Clin Rheumatol 2010, 29:913-920. 10.1007/s10067-010-1425-3, 2895904, 20496042.
36. Malviya A, Kuiper JH, Makwana N, Laing P, Ashton B. The effect of newer anti-rheumatic drugs on osteogenic cell proliferation: an in-vitro study. J Orthop Surg Res 2009, 4:17. 10.1186/1749-799X-4-17, 2694161, 19470170.
37. Rückemann K, Fairbanks LD, Carrey EA, Hawrylowicz CM, Richards DF, Kirschbaum B, Simmonds HA. Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans. J Biol Chem 1998, 273:21682-21691.
38. Montagna P, Brizzolara R, Soldano S, Pizzorni C, Sulli A, Cutolo M. Sex hormones and leflunomide treatment of human macrophage cultures: effects on apoptosis. Int J Clin Exp Med 2009, 2:221-232. 2777270, 19918315.
39. Pfeilschifter J, Mühl H, Pignat W, Märki F, van den Bosch H. Cytokine regulation of group II phospholipase A2 expression in glomerular mesangial cells. Eur J Clin Pharmacol 1993, 44(Suppl 1):S7-S9. 10.1007/BF01428384, 8387428.
40. Papadopoulos A, Ebrecht M, Roberts AD, Poon L, Rohleder N, Cleare AJ. Glucocorticoid receptor mediated negative feedback in chronic fatigue syndrome using the low dose (0.5 mg) dexamethasone suppression test. J Affect Disord 2009, 112:289-294. 10.1016/j.jad.2008.05.001, 18573538.
41. Turan A, Dalton JE, Turner PL, Sessler DI, Kurz A, Saager L. Preoperative prolonged steroid use is not associated with intraoperative blood transfusion in noncardiac surgical patients. Anesthesiology 2010, 113:285-291. 10.1097/ALN.0b013e3181e6a195, 20613467.
42. Pieringer H, Stuby U, Biesenbach G. Patients with rheumatoid arthritis undergoing surgery: how should we deal with antirheumatic treatment?. Semin Arthritis Rheum 2007, 36:278-286. 10.1016/j.semarthrit.2006.10.003, 17204310.